December 03, 2025 10:00 ET | Source: MATTER MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based…
LONDON, Dec. 2, 2025 /PRNewswire/ -- Yesterday, the Sustainable Markets Initiative hosted a gathering of Heads of States and Government,…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…
RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming facility, EU North Riga LV DC1, has been…
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Neurodon Corp., a leader in the development of endoplasmic reticulum (ER)…